Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.37
PXSLY's Cash to Debt is ranked higher than
54% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. PXSLY: 4.37 )
Ranked among companies with meaningful Cash to Debt only.
PXSLY' s Cash to Debt Range Over the Past 10 Years
Min: 1.76  Med: 8.43 Max: No Debt
Current: 4.37
Equity to Asset 0.35
PXSLY's Equity to Asset is ranked lower than
84% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. PXSLY: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
PXSLY' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.83 Max: 0.98
Current: 0.35
0.21
0.98
F-Score: 7
Z-Score: -2.07
M-Score: 5.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 28.84
PXSLY's Operating margin (%) is ranked higher than
91% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. PXSLY: 28.84 )
Ranked among companies with meaningful Operating margin (%) only.
PXSLY' s Operating margin (%) Range Over the Past 10 Years
Min: -291362.5  Med: -4122.83 Max: 24.78
Current: 28.84
-291362.5
24.78
Net-margin (%) 23.71
PXSLY's Net-margin (%) is ranked higher than
91% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. PXSLY: 23.71 )
Ranked among companies with meaningful Net-margin (%) only.
PXSLY' s Net-margin (%) Range Over the Past 10 Years
Min: -221662.5  Med: -3842.69 Max: 31.98
Current: 23.71
-221662.5
31.98
ROE (%) 56.57
PXSLY's ROE (%) is ranked higher than
97% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. PXSLY: 56.57 )
Ranked among companies with meaningful ROE (%) only.
PXSLY' s ROE (%) Range Over the Past 10 Years
Min: -120.56  Med: -32.12 Max: 67.9
Current: 56.57
-120.56
67.9
ROA (%) 19.76
PXSLY's ROA (%) is ranked higher than
93% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. PXSLY: 19.76 )
Ranked among companies with meaningful ROA (%) only.
PXSLY' s ROA (%) Range Over the Past 10 Years
Min: -57.89  Med: -28.14 Max: 24.74
Current: 19.76
-57.89
24.74
ROC (Joel Greenblatt) (%) 63.17
PXSLY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. PXSLY: 63.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PXSLY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -939.34  Med: -170.26 Max: 100.71
Current: 63.17
-939.34
100.71
Revenue Growth (3Y)(%) 233.80
PXSLY's Revenue Growth (3Y)(%) is ranked higher than
99% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. PXSLY: 233.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PXSLY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 18.60 Max: 233.8
Current: 233.8
0
233.8
» PXSLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with PXSLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:AMEX:AXN, NAS:ALIM, OTCPK:BIOYF, NAS:TNXP, NAS:ALQA, OTCPK:INNV, AMEX:NNVC, OTCPK:SUWN, NAS:ASMB, NAS:PRPH, OTCPK:NEVPF, OTCPK:CHEXF, NAS:IMNP, OTCPK:ECTE, OTCPK:NNAB, AMEX:CPHI, NAS:OASM, NAS:BSPM, OTCPK:ATHJF, OTCPK:INBP » details
Traded in other countries:PXS.Australia, UUD.Germany,
Pharmaxis Ltd is engaged in the research, development and commercialization of human healthcare products for the treatment and management of respiratory diseases. Its commercial product includes Aridol.

Pharmaxis Limited is an Australian specialty pharmaceutical company involved in the research, development and commercialization of healthcare products for chronic respiratory and immune diseases. The company produces Aridol, a powder which is used for the diagnosis and management of asthma and chronic obstructive pulmonary diseases. The company has sales and marketing group in Australia and has appointed marketing and distribution partners for certain European and Asian territories with respect to the marketing and sale of Aridol. They also manufacture Bronchitol, a drug used for chronic obstructive lung diseases like cystic fibrosis, bronchiectasis, and chronic bronchitis. The company has established offices In order to commercialize this product.

Ratios

vs
industry
vs
history
P/E(ttm) 5.60
PXSLY's P/E(ttm) is ranked higher than
96% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. PXSLY: 5.60 )
Ranked among companies with meaningful P/E(ttm) only.
PXSLY' s P/E(ttm) Range Over the Past 10 Years
Min: 3.56  Med: 4.24 Max: 6.1
Current: 5.6
3.56
6.1
PE(NRI) 7.00
PXSLY's PE(NRI) is ranked higher than
94% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. PXSLY: 7.00 )
Ranked among companies with meaningful PE(NRI) only.
PXSLY' s PE(NRI) Range Over the Past 10 Years
Min: 3.56  Med: 4.24 Max: 7
Current: 7
3.56
7
Price/Owner Earnings (ttm) 4.83
PXSLY's Price/Owner Earnings (ttm) is ranked higher than
95% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. PXSLY: 4.83 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PXSLY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.62  Med: 4.31 Max: 6.21
Current: 4.83
3.62
6.21
P/B 3.50
PXSLY's P/B is ranked lower than
58% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. PXSLY: 3.50 )
Ranked among companies with meaningful P/B only.
PXSLY' s P/B Range Over the Past 10 Years
Min: 0.32  Med: 3.08 Max: 9.72
Current: 3.5
0.32
9.72
P/S 1.51
PXSLY's P/S is ranked higher than
71% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. PXSLY: 1.51 )
Ranked among companies with meaningful P/S only.
PXSLY' s P/S Range Over the Past 10 Years
Min: 1.13  Med: 229.00 Max: 4180
Current: 1.51
1.13
4180
PFCF 4.06
PXSLY's PFCF is ranked higher than
95% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. PXSLY: 4.06 )
Ranked among companies with meaningful PFCF only.
PXSLY' s PFCF Range Over the Past 10 Years
Min: 3.04  Med: 3.62 Max: 5.22
Current: 4.06
3.04
5.22
POCF 4.00
PXSLY's POCF is ranked higher than
91% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. PXSLY: 4.00 )
Ranked among companies with meaningful POCF only.
PXSLY' s POCF Range Over the Past 10 Years
Min: 3  Med: 3.57 Max: 5.14
Current: 4
3
5.14
EV-to-EBIT 2.44
PXSLY's EV-to-EBIT is ranked higher than
98% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. PXSLY: 2.44 )
Ranked among companies with meaningful EV-to-EBIT only.
PXSLY' s EV-to-EBIT Range Over the Past 10 Years
Min: -21  Med: -5.10 Max: 3.2
Current: 2.44
-21
3.2
EV-to-EBITDA 2.08
PXSLY's EV-to-EBITDA is ranked higher than
98% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. PXSLY: 2.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
PXSLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.7  Med: -5.45 Max: 2.8
Current: 2.08
-21.7
2.8
Current Ratio 8.34
PXSLY's Current Ratio is ranked higher than
88% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. PXSLY: 8.34 )
Ranked among companies with meaningful Current Ratio only.
PXSLY' s Current Ratio Range Over the Past 10 Years
Min: 4.31  Med: 13.25 Max: 61.31
Current: 8.34
4.31
61.31
Quick Ratio 8.12
PXSLY's Quick Ratio is ranked higher than
89% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. PXSLY: 8.12 )
Ranked among companies with meaningful Quick Ratio only.
PXSLY' s Quick Ratio Range Over the Past 10 Years
Min: 4.04  Med: 13.24 Max: 61.31
Current: 8.12
4.04
61.31
Days Inventory 669.84
PXSLY's Days Inventory is ranked lower than
99% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. PXSLY: 669.84 )
Ranked among companies with meaningful Days Inventory only.
PXSLY' s Days Inventory Range Over the Past 10 Years
Min: 247.58  Med: 583.49 Max: 9125
Current: 669.84
247.58
9125
Days Sales Outstanding 27.26
PXSLY's Days Sales Outstanding is ranked higher than
87% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. PXSLY: 27.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
PXSLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.25  Med: 696.55 Max: 26918.75
Current: 27.26
36.25
26918.75
Days Payable 1.00
PXSLY's Days Payable is ranked lower than
98% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.26 vs. PXSLY: 1.00 )
Ranked among companies with meaningful Days Payable only.
PXSLY' s Days Payable Range Over the Past 10 Years
Min: 348.89  Med: 1318.06 Max: 148372.5
Current: 1
348.89
148372.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.45
PXSLY's Price/Net Cash is ranked lower than
99.99% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.32 vs. PXSLY: 9.45 )
Ranked among companies with meaningful Price/Net Cash only.
PXSLY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.48  Med: 5.46 Max: 15.78
Current: 9.45
1.48
15.78
Price/Net Current Asset Value 14.18
PXSLY's Price/Net Current Asset Value is ranked lower than
74% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. PXSLY: 14.18 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PXSLY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.42  Med: 4.90 Max: 18
Current: 14.18
1.42
18
Price/Tangible Book 3.51
PXSLY's Price/Tangible Book is ranked higher than
51% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.59 vs. PXSLY: 3.51 )
Ranked among companies with meaningful Price/Tangible Book only.
PXSLY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.78  Med: 3.33 Max: 8.4
Current: 3.51
0.78
8.4
Price/Median PS Value 0.01
PXSLY's Price/Median PS Value is ranked lower than
99.99% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. PXSLY: 0.01 )
Ranked among companies with meaningful Price/Median PS Value only.
PXSLY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.90 Max: 13.65
Current: 0.01
0.01
13.65
Price/Graham Number 1.04
PXSLY's Price/Graham Number is ranked higher than
81% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. PXSLY: 1.04 )
Ranked among companies with meaningful Price/Graham Number only.
PXSLY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.56  Med: 0.95 Max: 1.33
Current: 1.04
0.56
1.33
Earnings Yield (Greenblatt) (%) 41.00
PXSLY's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. PXSLY: 41.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PXSLY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 30.9  Med: 168.80 Max: 1648.4
Current: 41
30.9
1648.4

More Statistics

Revenue (TTM) (Mil) $44.91
EPS (TTM) $ 0.54
Beta-1.81
Short Percentage of Float0.00%
52-Week Range $2.02 - 5.60
Shares Outstanding (Mil)21.14

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)